Trillium Therapeutics Inc. (TTI) is a privately-owned biopharmaceutical company with two main areas of focus: cytoprotection and immune regulation. The Company’s cytoprotection programs are based upon a recombinant form of heparin-binding epidermal growth factor-like growth factor (HB-EGF).